ClinicalTrials.gg
RecruitingNCT06892522Updated Oct 19, 2026

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

A Phase 1/2 interventional study of Etentamig and Lenalidomide in Multiple Myeloma, sponsored by AbbVie. Recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Oct 19, 2026Study completion movedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.

Planned enrollment
2nd of 10
602 · median 235
Started
2025
with 1 other
Phase 1/2
3 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
9 of 10
AbbVie

Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1/2, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About etentamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing etentamig in Multiple Myeloma, or all of them as a file.
02

Study summary

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM.

Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd and R. Participants in substudies 5-8 will receive up to two doses of ABBV-2001 or at the dose level(s) established during the escalation phases of ABBV-2001 with iberdomide, mezigdomide, pomalidomide or lenalidomide. Around 602 adult participants with MM will be enrolled at approximately 55 sites worldwide

In substudies 1-3, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or with DR, R or Kd, followed by SC injections of etentamig at the dose levels established during the escalation phases alone or with DR or K. In substudy 4, participants will receive escalating doses of etentamig as Intravenous (IV) infusions followed by SC injections of etentamig at the dose levels established during the escalation phase with Lenalidomide. In substudies 5-8, participants will receive up to two doses of ABBV-2001 as subcutaneous (SC) injections, with oral iberdomide, mezigdomide, pomalidomide or lenalidomide followed by SC injections of ABBV-2001 at the dose level(s) established during the escalation phases with oral iberdomide, mezigdomide, pomalidomide or lenalidomide. The study duration is approximately 130 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma, Etentamig, ABBV-383, Cancer
  • Daratumumab
  • Lenalidomide
  • Dexamethasone
  • Carfilzomib
  • ABBV-2001
  • Iberdomide
  • Mezigdomide
  • Pomalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance of \<= 1.
  • Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or (RR) MM, depending on the substudy.

Exclusion criteria

Exclusion Criteria:

  • Participant who has known active central nervous system involvement of MM.
  • Participant who has known active infection as outlined in the protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
602 participants (estimated)

Study arms

  • Experimental
    Substudy 1: Etentamig Dose Escalation

    Participants will receive escalating etentamig in combination with daratumumab, and lenalidomide (DR), as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Lenalidomide · Drug: Daratumumab

  • Experimental
    Substudy 1: Etentamig Dose Expansion

    Participants will receive a recommended dose of etentamig in combination with DR, as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Lenalidomide · Drug: Daratumumab

  • Experimental
    Substudy 2: Etentamig Dose Escalation

    Participants will receive escalating etentamig, as part of the approximately 130 month study duration.

    Drug: Etentamig

  • Experimental
    Substudy 2: Etentamig Dose Expansion

    Participants will receive a recommended dose of etentamig, as part of the approximately 130 month study duration.

    Drug: Etentamig

  • Experimental
    Substudy 3: Etentamig Dose Escalation

    Participants will receive escalating etentamig in combination with carfilzomib, and dexamethasone (Kd), as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Substudy 3: Etentamig Dose Expansion

    Participants will receive a recommended dose of etentamig in combination with carfilzomib (k), as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Substudy 4: Etentamig Dose Escalation

    Participants will receive escalating etentamig in combination with R, as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Lenalidomide

  • Experimental
    Substudy 4: Etentamig Dose Expansion

    Participants will receive a recommended dose of etentamig in combination with R, as part of the approximately 130 month study duration.

    Drug: Etentamig · Drug: Lenalidomide

  • Experimental
    Substudy 5: ABBV-2001 Dose Escalation

    Participants will receive up to two doses of ABBV-2001 in combination with iberdomide, as part of the approximately 130 month study duration.

    Drug: Iberdomide · Drug: ABBV-2001

  • Experimental
    Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 1

    Participants will receive ABBV-2001 in combination with iberdomide at the combo dose level 1, as part of the approximately 130 month study duration.

    Drug: Iberdomide · Drug: ABBV-2001

  • Experimental
    Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 2

    Participants will receive ABBV-2001 in combination with iberdomide, at the combo dose level 2, as part of the approximately 130-month study duration.

    Drug: Iberdomide · Drug: ABBV-2001

  • Experimental
    Substudy 6: ABBV-2001 Dose Escalation

    Participants will receive up to two doses of ABBV-2001 in combination with mezigdomide, as part of the approximately 130 month study duration.

    Drug: Mezigdomide · Drug: ABBV-2001

  • Experimental
    Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 1

    Participants will receive ABBV-2001 in combination with mezigdomide, at the combo dose level 1, as part of the approximately 130-month study duration.

    Drug: Mezigdomide · Drug: ABBV-2001

  • Experimental
    Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 2

    Participants will receive ABBV-2001 in combination with mezigdomide, at the combo dose level 2, as part of the approximately 130-month study duration.

    Drug: Mezigdomide · Drug: ABBV-2001

  • Experimental
    Substudy 7: ABBV-2001 Dose Escalation

    Participants will receive up to two doses of ABBV-2001 in combination with pomalidomide, as part of the approximately 130 month study duration.

    Drug: ABBV-2001 · Drug: Pomalidomide

  • Experimental
    Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1

    Participants will receive ABBV-2001 in combination with pomalidomide, at the combo dose level 1, as part of the approximately 130-month study duration.

    Drug: ABBV-2001 · Drug: Pomalidomide

  • Experimental
    Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2

    Participants will receive ABBV-2001 in combination with pomalidomide, at the combo dose level 2, as part of the approximately 130-month study duration.

    Drug: ABBV-2001 · Drug: Pomalidomide

  • Experimental
    Substudy 8: ABBV-2001 Dose Escalation

    Participants will receive up to two doses of ABBV-2001 in combination with lenalidomide, as part of the approximately 130 month study duration.

    Drug: Lenalidomide · Drug: ABBV-2001

  • Experimental
    Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1

    Participants will receive ABBV-2001 in combination with lenalidomide, at the combo dose level 1, as part of the approximately 130-month study duration.

    Drug: Lenalidomide · Drug: ABBV-2001

  • Experimental
    Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2

    Participants will receive ABBV-2001 in combination with lenalidomide, at the combo dose level 2, as part of the approximately 130-month study duration.

    Drug: Lenalidomide · Drug: ABBV-2001

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)s

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 130 Months

  2. Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 weeks

  3. Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  4. Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  5. Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMM

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  6. Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MM

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  7. Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MM

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  8. Substudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MM

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

  9. Substudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MM

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 8 Weeks

Secondary outcomes

  1. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Complete Response Rate

    Complete response rate is defined as complete response (CR), stringent complete response (sCR) as assessed by the international myeloma working group (IMWG) 2016 criteria for MM.

    Time frame: Up to Approximately 1 Year

  2. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Overall Response Rate (ORR)

    The ORR is defined as the percentage of participants who achieve a best overall response of confirmed PR or better determined by IMWG criteria, prior to the initiation of subsequent myeloma therapy.

    Time frame: Up to Approximately 1 Year

  3. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Progression Free Survival (PFS)

    PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IMWG) or death.

    Time frame: Up to Approximately 130 Months

  4. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Duration of Response (DOR)

    DOR is defined as the time from the date of first response to the earliest occurrence of progressive disease, or death, whatever occurs first.

    Time frame: Up to Approximately 130 Months

  5. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Time-to-Progression (TTP)

    TTP will be defined as the number of days from the date of first dose to the date of earliest disease progression.

    Time frame: Up to Approximately 130 Months

  6. Substudy 1, 2, 3, 4, 5, 6, 7, 8: Minimal Residual Disease (MRD) negativity

    The MRD negativity rate is defined as the proportion of participants who achieve MRD negative status.

    Time frame: Up to Approximately 52 Weeks

07

Study locations

36 of 36 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2035, 126 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 126 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2035 → Mar 2036, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 24, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Dec 2035
CompletionEst.
Mar 2036was Dec 2035
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 United States, 1 Japan)
  • University Of California, San Francisco /ID# 271662 · San Francisco, United States
  • Japanese Red Cross Medical Center /ID# 273530 · Shibuya-ku, Japan
Oct 19, 2026
Study completion
Dec 2035→Mar 2036
Oct 19, 2026
Interventions
Added Drug: Etentamig·Drug: Pomalidomide. Arm changed Substudy 1: Etentamig Dose Expansion Dose Level 1→Substudy 1: Etentamig Dose Expansion; Substudy 1: Etentamig Dose Expansion Dose Level 2→Substudy 2: Etentamig Dose Expansion; Substudy 2: Etentamig Dose Expansion Dose Level 1→Substudy 3: Etentamig Dose Expansion; Substudy 2: Etentamig Dose Expansion Dose Level 2→Substudy 4: Etentamig Dose Expansion; Substudy 5: ABBV-2001 Dose Expansion Dose Level 1→Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 1; Substudy 5: ABBV-2001 Dose Expansion Dose Level 2→Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 2; Substudy 6: ABBV-2001 Dose Expansion Dose Level 1→Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 1; Substudy 6: ABBV-2001 Dose Expansion Dose Level 2→Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 2. Arms added: Substudy 7: ABBV-2001 Dose Escalation·Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1·Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2·Substudy 8: ABBV-2001 Dose Escalation·Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1·and 1 more
All 6

Substudy 7: ABBV-2001 Dose Escalation · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1 · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2 · Substudy 8: ABBV-2001 Dose Escalation · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1 · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2

; arms removed: Substudy 1: Comparator·Substudy 2: Comparator·Substudy 3: Etentamig Dose Expansion Dose Level 1·Substudy 3: Etentamig Dose Expansion Dose Level 2·Substudy 3: Comparator·and 2 more
All 7

Substudy 1: Comparator · Substudy 2: Comparator · Substudy 3: Etentamig Dose Expansion Dose Level 1 · Substudy 3: Etentamig Dose Expansion Dose Level 2 · Substudy 3: Comparator · Substudy 4: Etentamig Dose Expansion Dose Level 1 · Substudy 4: Etentamig Dose Expansion Dose Level 2

Oct 19, 2026
Primary outcomes
2 added
What changed in the outcomes
  • AddedSubstudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
  • AddedSubstudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
Oct 19, 2026
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Complete Response RateTime frame: Up to Approximately 1 Year
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Overall Response Rate (ORR)Time frame: Up to Approximately 1 Year
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Progression Free Survival (PFS)Time frame: Up to Approximately 130 Months
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Duration of Response (DOR)Time frame: Up to Approximately 130 Months
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Time-to-Progression (TTP)Time frame: Up to Approximately 130 Months
  • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Minimal Residual Disease (MRD) negativityTime frame: Up to Approximately 52 Weeks
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    2 sites added
    Show 2 added (1 United States, 1 Japan)
    • University Of California, San Francisco /ID# 271662 · San Francisco, United States
    • Japanese Red Cross Medical Center /ID# 273530 · Shibuya-ku, Japan
    Study completion Dec 2035→Mar 2036
    Primary outcomes 2 added
    What changed in the outcomes
    • AddedSubstudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
    • AddedSubstudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Complete Response RateTime frame: Up to Approximately 1 Year
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Overall Response Rate (ORR)Time frame: Up to Approximately 1 Year
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Progression Free Survival (PFS)Time frame: Up to Approximately 130 Months
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Duration of Response (DOR)Time frame: Up to Approximately 130 Months
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Time-to-Progression (TTP)Time frame: Up to Approximately 130 Months
    • EditedSubstudy 1, 2, 3, 4, 5, 6, 7, 8: Minimal Residual Disease (MRD) negativityTime frame: Up to Approximately 52 Weeks
    Interventions Added Drug: Etentamig·Drug: Pomalidomide. Arm changed Substudy 1: Etentamig Dose Expansion Dose Level 1→Substudy 1: Etentamig Dose Expansion; Substudy 1: Etentamig Dose Expansion Dose Level 2→Substudy 2: Etentamig Dose Expansion; Substudy 2: Etentamig Dose Expansion Dose Level 1→Substudy 3: Etentamig Dose Expansion; Substudy 2: Etentamig Dose Expansion Dose Level 2→Substudy 4: Etentamig Dose Expansion; Substudy 5: ABBV-2001 Dose Expansion Dose Level 1→Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 1; Substudy 5: ABBV-2001 Dose Expansion Dose Level 2→Substudy 5: ABBV-2001 + Iberdomide at Combo Dose Level 2; Substudy 6: ABBV-2001 Dose Expansion Dose Level 1→Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 1; Substudy 6: ABBV-2001 Dose Expansion Dose Level 2→Substudy 6: ABBV-2001 + Mezigdomide at Combo Dose Level 2. Arms added: Substudy 7: ABBV-2001 Dose Escalation·Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1·Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2·Substudy 8: ABBV-2001 Dose Escalation·Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1·and 1 more
    All 6

    Substudy 7: ABBV-2001 Dose Escalation · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 1 · Substudy 7: ABBV-2001 + Pomalidomide at Combo Dose Level 2 · Substudy 8: ABBV-2001 Dose Escalation · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 1 · Substudy 8: ABBV-2001 + Lenalidomide at Combo Dose Level 2

    ; arms removed: Substudy 1: Comparator·Substudy 2: Comparator·Substudy 3: Etentamig Dose Expansion Dose Level 1·Substudy 3: Etentamig Dose Expansion Dose Level 2·Substudy 3: Comparator·and 2 more
    All 7

    Substudy 1: Comparator · Substudy 2: Comparator · Substudy 3: Etentamig Dose Expansion Dose Level 1 · Substudy 3: Etentamig Dose Expansion Dose Level 2 · Substudy 3: Comparator · Substudy 4: Etentamig Dose Expansion Dose Level 1 · Substudy 4: Etentamig Dose Expansion Dose Level 2

    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06892522
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jun 30, 2025
Primary completion
Dec 2035 (estimated)
Completion
Mar 2036 (estimated)
Last update
Oct 19, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etentamig · Lenalidomide

Start the discussion